The effect of explanation and demonstration of topical therapy on the clinical response of atopic eczema

ABSTRACT

Background Atopic eczema is a common dermatological condition seen in our practice in which the mainstay of treatment is topical medications. One of the main reasons for poor clinical response to therapy in atopic eczema is the lack of understanding of topical preparation usage and thus poor adherence to treatment. Objectives The aim of this study is to determine the effect of explanation and demonstration of topical medication on the clinical response of atopic eczema. Methodology Twenty newly diagnosed patients with atopic eczema who fulfilled the study criteria were recruited and randomized consecutively into 2 groups - A & B. All patients were assessed on the severity of the eczema using the six area, six sign atopic dermatitis severity score (SASSAD) and patients’ assessment of itch, sleep disturbance and irritability were recorded on 10-cm visual analogue scales. They were also assessed on their level of understanding on the proper usage of topical medications using a questionnaire. Group A then received explanation and demonstration on how to apply the topical medications while Group B was not educated on these. They were followed up 2 weeks after treatment and were re-evaluated on their understanding and the severity of their skin condition. This was followed by education by a dermatology nurse on the proper usage of topical medications for both groups. A third evaluation was done 2 weeks later. Results At baseline, 70% of the patients did not understand the potency of topical corticosteroid and between 20-30% of them did not know the correct sites, frequency, time and duration of each topical application prescribed. About two thirds of the patients claimed that they did not receive any explanation or demonstration from either their doctors or the pharmacy dispensers. After education on the proper usage of topical medications, the level of understanding improved to 100% for group A at visit 2 and group B at visit 3. A clinical improvement as measured by SASSAD score reduction was seen in both groups. In group A, a significant SASSAD score reduction of 49.5% (P=0.003) was seen after 2 weeks and it was sustainable, as evidenced by a further reduction to 67% (p=0.001) by week 4. In group B, a significant SASSAD score reduction (64.8%; p=0.002) was seen only at week 4 after patient education and demonstration. The magnitude of improvement in patients’ symptoms which included itch, sleep disturbance and irritability, measured by the patient using visual analog score, were only significant for group A after 4 weeks. Conclusions This study reinforces the importance of explanation and demonstration on the proper usage of topical medications in achieving better clinical response. Failure to explain on the use of topical medications may lead to patient dissatisfaction, poor compliance and lack of treatment efficacy.